Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roivant Sciences ( (ROIV) ) has provided an update.
On September 3, 2025, Roivant Sciences announced promising results from a proof-of-concept study conducted by its subsidiary, Immunovant, on the treatment of uncontrolled Graves’ Disease using batoclimab. The study revealed that approximately 80% of patients maintained normal thyroid function six months after treatment, with around 50% achieving remission without anti-thyroid drugs. These findings suggest a potential shift in the treatment paradigm for Graves’ Disease, with two registrational trials for IMVT-1402 currently enrolling and results expected in 2027.
The most recent analyst rating on (ROIV) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.
Spark’s Take on ROIV Stock
According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.
Roivant Sciences’ overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and persistent losses. While technical indicators suggest a neutral to slightly bullish trend, the negative valuation metrics highlight concerns about the stock’s current pricing. The positive sentiment from the earnings call and corporate events, such as the share repurchase program, provide some optimism but are not enough to offset the financial difficulties.
To see Spark’s full report on ROIV stock, click here.
More about Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on accelerating the development and commercialization of impactful medicines. Its subsidiary, Immunovant, Inc., is a clinical-stage immunology company pioneering anti-FcRn technology to develop targeted therapies for autoimmune diseases.
Average Trading Volume: 5,725,925
Technical Sentiment Signal: Buy
Current Market Cap: $8.15B
See more insights into ROIV stock on TipRanks’ Stock Analysis page.